These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22029524)

  • 1. Uncommon yeast infections in hematological patients: from diagnosis to treatment.
    Caira M; Trecarichi EM; Tumbarello M; Leone G; Pagano L
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1067-75. PubMed ID: 22029524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
    Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
    Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances and challenges in the treatment of invasive fungal infections.
    Shao PL; Huang LM; Hsueh PR
    Int J Antimicrob Agents; 2007 Dec; 30(6):487-95. PubMed ID: 17961990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
    Almyroudis NG; Segal BH
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin.
    Matsue K; Uryu H; Koseki M; Asada N; Takeuchi M
    Clin Infect Dis; 2006 Mar; 42(6):753-7. PubMed ID: 16477548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy.
    Pagano L; Caira M; Fianchi L
    Ann Med; 2005; 37(4):259-69. PubMed ID: 16019724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal Trichosporon fungemia in patients with hematologic malignancies.
    Suzuki K; Nakase K; Kyo T; Kohara T; Sugawara Y; Shibazaki T; Oka K; Tsukada T; Katayama N
    Eur J Haematol; 2010 May; 84(5):441-7. PubMed ID: 20059528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current therapeutic approaches to fungal infections in immunocompromised hematological patients.
    Pagano L; Caira M; Valentini CG; Posteraro B; Fianchi L
    Blood Rev; 2010 Mar; 24(2):51-61. PubMed ID: 20056300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal prophylaxis and treatment in patients with hematological malignancies.
    Hwang YY; Liang R
    Expert Rev Anti Infect Ther; 2010 Apr; 8(4):397-404. PubMed ID: 20377335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fungal infections in cancer patients: an escalating problem.
    Samonis G; Bafaloukos D
    In Vivo; 1992; 6(2):183-93. PubMed ID: 1525339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in antifungal prevention and treatment.
    Groll AH; Tragiannidis A
    Semin Hematol; 2009 Jul; 46(3):212-29. PubMed ID: 19549575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B: what is its role in 2008?
    Lanternier F; Lortholary O
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():71-83. PubMed ID: 18430132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging life-threatening opportunistic fungal pathogen Kodamaea ohmeri: optimal treatment and literature review.
    Shang ST; Lin JC; Ho SJ; Yang YS; Chang FY; Wang NC
    J Microbiol Immunol Infect; 2010 Jun; 43(3):200-6. PubMed ID: 21291847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.
    Girmenia C; Pagano L; Martino B; D'Antonio D; Fanci R; Specchia G; Melillo L; Buelli M; Pizzarelli G; Venditti M; Martino P;
    J Clin Microbiol; 2005 Apr; 43(4):1818-28. PubMed ID: 15815003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of invasive fungal infections: a role for polyenes.
    Chandrasekar P
    J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances].
    Cuenca-Estrella M
    Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
    Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
    Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies.
    Hoenigl M; Zollner-Schwetz I; Sill H; Linkesch W; Lass-Flörl C; Schnedl WJ; Krause R
    Mycoses; 2011 Sep; 54(5):454-9. PubMed ID: 20406398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.